Aardvark’s Hunger-Suppressing Drug Promises Weight Loss Without GI Distress

All NewsJune 30, 2025

Aardvark’s lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent